Hodgkin Lymphoma   

The current NCCN guideline version 2.2021 is a little confusing. On page HODG-2,  the clinical staging/risk classification did not include ESR, b...

Have the RAPID or CALGB 5064 studies changed your treatment approach?

NCCN recommends either ISRT with rituximab/chemotherapy or ISRT alone in this scenario.  What factors help your decision making?

There are conflicting reports of increased incidence of bleomycin-induced lung toxicity with G-CSF.

Would you still proceed to high-dose therapy and autologous SCT? Would you incorporate radiation pre- or post- transplant? Or offer additional salvag...

Although not approved, for example, are you every using AVD-nivolumab?

Would the site of disease relapse play a role in your decision (i.e. isolated lymph node recurrence versus failure at primary site of disease)?